Comprehensive in-silico analysis of damage associated SNPs in hOCT1 affecting Imatinib response in chronic myeloid leukemia

Genomics. 2021 Jan;113(1 Pt 2):755-766. doi: 10.1016/j.ygeno.2020.10.007. Epub 2020 Oct 16.

Abstract

Non-synonymous single nucleotide polymorphisms (nsSNPs) in hOCT1 (encoded by SLC22A1 gene) are expected to affect Imatinib uptake in chronic myeloid leukemia (CML). In this study, sequence homology-based genetic analysis of a set of 270 coding SNPs identified 18 nsSNPs to be putatively damaging/deleterious using eight different algorithms. Subsequently, based on conservation of amino acid residues, stability analysis, posttranscriptional modifications, and solvent accessibility analysis, the possible structural-functional relationship was established for high-confidence nsSNPs. Furthermore, based on the modeling results, some dissimilarities of mutant type amino acids from wild-type amino acids such as size, charge, interaction and hydrophobicity were revealed. Three highly deleterious mutations consisting of P283L, G401S and R402G in SLC22A1 gene that may alter the protein structure, function and stability were identified. These results provide a filtered data to explore the effect of uncharacterized nsSNP and find their association with Imatinib resistance in CML.

Keywords: CML; Imatinib resistance; In silico analysis; hOCT1; nsSNP.

MeSH terms

  • Amino Acid Substitution
  • Antineoplastic Agents / therapeutic use
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Molecular Dynamics Simulation
  • Octamer Transcription Factor-1 / chemistry
  • Octamer Transcription Factor-1 / genetics*
  • Octamer Transcription Factor-1 / metabolism
  • Polymorphism, Single Nucleotide*

Substances

  • Antineoplastic Agents
  • Octamer Transcription Factor-1
  • POU2F1 protein, human
  • Imatinib Mesylate